Navigation Links
Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
Date:5/17/2010

,060,000 shares issued and outstanding at March 31, 2010 and December 31, 2009 1,467 3,060 Common stock, $.001 par value, 100,000,000 shares authorized, 25,820,119 and 23,374,799 shares issued and outstanding at March 31, 2010 and December 31, 2009 25,820 23,375 Additional paid-in capital 19,992,542 19,801,366 Statutory reserve 3,119,132 2,860,685 Retained earnings 19,553,544 17,548,676 Accumulated other comprehensive income 679,655 682,709 Total Stockholders' Equity 43,372,160 40,919,871 Total Liabilities and Stockholders' Equity $48,926,823 $47,010,469 BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED Three Months Ended March 31, 2010 2009 Sales, net $12,363,175 $7,447,664 Cost of sales 2,840,426 2,658,807 Gross profit 9,522,749 4,788,857 Operating expenses: Selling and distribution 5,609,561 1,888,182 General and administrative 625,722 591,802 Stock-based compensation 154,490 -- Total operating expenses 6,389,773 2,479,984 Income from operations 3,132,976 2,308,873 Other Income (Expense) Interest income 3,686 310 Other expense (6,131) -- Foreign excha
'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
2. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
3. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
6. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
7. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
8. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
10. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
11. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Mich., Sept. 23 Sanford Rose Associates®-Rochester, an ... Rose Associates® network of offices, was recently named ... Sanford Rose Associates®-Rochester was established in January 2009 ... professional searches in the automotive, alternative energy, defense, ...
... BEACH, Calif., Sept. 23 Genesis Biopharma, Inc. (OTC Bulletin ... cancer therapies, today announced that it has closed a private ... accredited investors to purchase 933,341 shares of its common stock ... Series A warrants to purchase 466,674 shares at an exercise ...
... Association (BMA) Award Winning Medical Authors and Editors -- LONDON, September 23, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:Genesis Biopharma Announces $700K Private Financing 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 3Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 4Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 5Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 6Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 7Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 8
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Mich. Ask any political leader if they are ... typically a resounding, "Yes." Evaluating its effectiveness, however, ... and environmental science and policy professor at Michigan State ... evaluate sustainability at a national gathering of scientists Feb. ...
... NC How did early humans adapt to different climates and ... the globe? And what does that mean for humans living today? ... and anthropology will present their findings on Sunday February 20th at ... titled "Humans Without Borders: Evolutionary Processes at Work In Humans ...
... At this year,s American Association for the Advancement ... to 21, Caltech researchers will present topics ranging from ... in bioengineering. Caltech,s Alice S. Huang, AAAS president, ... highlighting this year,s AAAS theme, "Science Without Borders." ...
Cached Biology News:It's time to take a unified approach toward measuring sustainability 2Panelists to discuss evolution of human brain size, skin color and diet at AAAS meeting 2Tip sheet: Caltech researchers presenting at AAAS 2Tip sheet: Caltech researchers presenting at AAAS 3
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
... is designed for use with HRP conjugated rabbit ... mouse monoclonal coating antibody. • ... prevent non-specific binding between the coating and detection ... may be used to stabilize newly conjugated antibodies, ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Biology Products: